Search

Your search keyword '"Garming Legert, Karin"' showing total 28 results
Start Over Author "Garming Legert, Karin" Publication Year Range Last 50 years
28 results on '"Garming Legert, Karin"'

4. Oral health in patients scheduled for hematopoietic stem cell transplantation in the Orastem study

Author

Skallsjö, Kristina, primary, von Bültzingslöwen, Inger, additional, Hasséus, Bengt, additional, Johansson, Jan-Erik, additional, Öhman, Jenny, additional, Raber-Durlacher, Judith E., additional, Huysmans, Marie-Charlotte D. N. J. M., additional, Laheij, Alexa M. G. A., additional, van Leeuwen, Stephanie J. M., additional, Hovan, Allan J., additional, Garming Legert, Karin, additional, Nguyen, Hieu M., additional, Turk, Philip J., additional, Rozema, Frederik R., additional, Blijlevens, Nicole M. A., additional, and Brennan, Michael T., additional

Published
2023
Full Text
View/download PDF

7. Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT)

Author

Elad, Sharon, Raber-Durlacher, Judith E., Brennan, Michael T., Saunders, Deborah P., Mank, Arno P., Zadik, Yehuda, Quinn, Barry, Epstein, Joel B., Blijlevens, Nicole M. A., Waltimo, Tuomas, Passweg, Jakob R., Correa, M. Elvira P., Dahllöf, Göran, Garming-Legert, Karin U. E., Logan, Richard M., Potting, Carin M. J., Shapira, Michael Y., Soga, Yoshihiko, Stringer, Jacqui, Stokman, Monique A., Vokurka, Samuel, Wallhult, Elisabeth, Yarom, Noam, and Jensen, Siri Beier

Published
2015
Full Text
View/download PDF

9. Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study

Author

Remberger, Mats, Ackefors, Malin, Berglund, Sofia, Blennow, Ola, Dahllöf, Göran, Dlugosz, Aldona, Garming-Legert, Karin, Gertow, Jens, Gustafsson, Britt, Hassan, Moustapha, Hassan, Zuzana, Hauzenberger, Dan, Hägglund, Hans, Karlsson, Helen, Klingspor, Lena, Kumlien, Gunilla, Le Blanc, Katarina, Ljungman, Per, Machaczka, Maciej, Malmberg, Karl-Johan, Marschall, Hanns-Ulrich, Mattsson, Jonas, Olsson, Richard, Omazic, Brigitta, Sairafi, Darius, Schaffer, Marie, Svahn, Britt-Marie, Svenberg, Petter, Swartling, Lisa, Szakos, Attila, Uhlin, Michael, Uzunel, Mehmet, Watz, Emma, Wernerson, Annika, Wikman, Agneta, Wikström, Ann-Charlotte, Winiarski, Jacek, and Ringdén, Olle

Published
2011
Full Text
View/download PDF

10. Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial

Author

Walladbegi, Java, primary, Henriksson, Roger, additional, Tavelin, Björn, additional, Svanberg, Anncarin, additional, Larfors, Gunnar, additional, Jädersten, Martin, additional, Schjesvold, Fredrik, additional, Mahdi, Aram, additional, Garming Legert, Karin, additional, Peterson, Douglas E., additional, and Jontell, Mats, additional

Published
2021
Full Text
View/download PDF

15. Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft‐versus‐host disease prophylaxis.

Author

Garming Legert, Karin, Ringdén, Olle, Remberger, Mats, Törlén, Johan, Mattsson, Jonas, and Dahllöf, Göran

Subjects
*GRAFT versus host disease prevention, *STOMATITIS, *RAPAMYCIN, *TIME, *CONVALESCENCE, *CYCLOSPORINE, *METHOTREXATE, *SEVERITY of illness index, *HEMATOPOIETIC stem cell transplantation, *STATISTICAL sampling, *TACROLIMUS
Abstract

Objectives: To determine whether treatment with tacrolimus plus sirolimus (Tac/Sir) as a prophylaxis for graft‐versus‐host disease worsens severe oral mucositis and delays healing compared to cyclosporine plus methotrexate (CsA/Mtx) following haematopoietic stem cell transplantation. Subjects and Methods: The study comprised 141 patients: 73 randomized to receive Tac/Sir and 68 to receive CsA/Mtx. The oral mucositis assessment scale and toxicity grading according to WHO were used to assess the severity, peak and duration of oral mucositis from the day −3 to day 24 post‐transplant. Results: Eighty‐seven patients developed oral mucositis in the first 24 days post‐transplant. No significant difference in oral mucositis severity between the Tac/Sir and CsA/Mtx groups was observed. The peak oral mucositis score occurred on day 10 in both groups. Although oral mucositis scores had returned to baseline in the CsA/Mtx group on day 24 post‐transplant, no significant difference compared with the Tac/Sir group was found. Conclusions: The introduction of tacrolimus/sirolimus as a graft‐versus‐host disease prophylaxis in haematopoietic stem cell transplantation increased neither the incidence nor severity of oral mucositis compared with cyclosporine/methotrexate. Furthermore, oral mucositis healing was not prolonged and followed the same time pattern as cyclosporine/methotrexate. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. Impact of Oral Side Effects from Conditioning Therapy Before Hematopoietic Stem Cell Transplantation: Protocol for a Multicenter Study

Author

Brennan, Michael T, primary, Hasséus, Bengt, additional, Hovan, Allan J, additional, Raber-Durlacher, Judith E, additional, Blijlevens, Nicole MA, additional, Huysmans, Marie-Charlotte, additional, Garming Legert, Karin, additional, Johansson, Jan-Erik, additional, Moore, Charity G, additional, and von Bültzingslöwen, Inger, additional

Published
2018
Full Text
View/download PDF

20. Treatment of chronic GvHDwith mesenchymal stromal cells induces durable responses: A phase IIstudy

Author

Boberg, Erik, Bahr, Lena, Afram, Gabriel, Lindström, Carina, Ljungman, Per, Heldring, Nina, Petzelbauer, Peter, Garming Legert, Karin, Kadri, Nadir, and Le Blanc, Katarina

Abstract

Steroid‐refractory chronic graft‐vs‐host disease (cGvHD) contributes to morbidity after allogeneic hematopoietic stem cell transplantation. Here, we report on 11 patients with severe, refractory cGvHD treated with repeated infusions of allogeneic bone marrow‐derived mesenchymal stromal cells (MSC) over a 6‐ to 12‐month period. Six patients responded to MSC treatment following National Institutes of Health response criteria, accompanied by improvement in GvHD‐related symptoms and quality of life. This response was durable, with systemic immunosuppressive therapy withdrawn from two responders, and a further two free from steroids and tapering calcineurin inhibitors. All responders displayed a distinct immune phenotype characterized by higher levels of naïve T cells and B cells before treatment compared with the nonresponders, and a significantly higher fraction of CD31+ naïve CD4+ T cells. MSC treatment was associated with significant increases in naïve T cells, B cells, and Tregs 7 days after each infusion. Skin biopsies showed resolution of epidermal pathology. CXCL9 and CXCL10 showed differential responses in responder and nonresponder patients. Our data support the use of MSC infusions as treatment for steroid‐refractory cGvHD with durable responses. We propose CXCL9 and CXCL10 as early biomarkers for responsiveness to MSC treatment. Our results highlight the importance of the MSC recipient immune phenotype in promoting treatment response. This trial was registered at www.ClinicalTrials.govas #NCT01522716. A, In this clinical phase II study, 11 patients with severe, refractory chronic graft‐vs‐host disease (cGvHD) were treated with repeated monthly infusions of mesenchymal stromal cell (MSC). B, Six patients responded with a reduction in disease severity as measured by the National Institutes of Health score. Immunological analysis revealed that response was associated with an immune profile with increased naïve CD4+ T‐cell and Treg numbers. In addition, a better thymic function in the responders was suggested based on increased ratio of recent thymic emigrants among naïve CD4+ T cells. Short‐term after each infusion we observed an increase in CD4+ T‐cell and Treg numbers in the responders. Skin histology improved in both groups with reduced epidermal inflammation. Our results support the use of MSC infusions for refractory cGvHD and suggest the recipient immune system phenotype as a predictor of responsiveness. R, responder; NR, nonresponder.

Published
2020
Full Text
View/download PDF

21. Impact of Oral Side Effects from Conditioning Therapy Before Hematopoietic Stem Cell Transplantation: Protocol for a Multicenter Study (Preprint)

Author

Brennan, Michael T, primary, Hasséus, Bengt, additional, Hovan, Allan J, additional, Raber-Durlacher, Judith E, additional, Blijlevens, Nicole MA, additional, Huysmans, Marie-Charlotte, additional, Garming Legert, Karin, additional, Johansson, Jan-Erik, additional, Moore, Charity G, additional, and von Bültzingslöwen, Inger, additional

Published
2017
Full Text
View/download PDF

22. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation

Author

Törlén, Johan, primary, Ringdén, Olle, additional, Garming-Legert, Karin, additional, Ljungman, Per, additional, Winiarski, Jacek, additional, Remes, Kari, additional, Itälä-Remes, Maija, additional, Remberger, Mats, additional, and Mattsson, Jonas, additional

Published
2016
Full Text
View/download PDF

24. Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT)

Author

Elad, Sharon, primary, Raber-Durlacher, Judith E., additional, Brennan, Michael T., additional, Saunders, Deborah P., additional, Mank, Arno P., additional, Zadik, Yehuda, additional, Quinn, Barry, additional, Epstein, Joel B., additional, Blijlevens, Nicole M. A., additional, Waltimo, Tuomas, additional, Passweg, Jakob R., additional, Correa, M. Elvira P., additional, Dahllöf, Göran, additional, Garming-Legert, Karin U. E., additional, Logan, Richard M., additional, Potting, Carin M. J., additional, Shapira, Michael Y., additional, Soga, Yoshihiko, additional, Stringer, Jacqui, additional, Stokman, Monique A., additional, Vokurka, Samuel, additional, Wallhult, Elisabeth, additional, Yarom, Noam, additional, and Jensen, Siri Beier, additional

Published
2014
Full Text
View/download PDF

25. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease

Author

Munneke, J. Marius, primary, Björklund, Andreas T., additional, Mjösberg, Jenny M., additional, Garming-Legert, Karin, additional, Bernink, Jochem H., additional, Blom, Bianca, additional, Huisman, Cynthia, additional, van Oers, Marinus H. J., additional, Spits, Hergen, additional, Malmberg, Karl-Johan, additional, and Hazenberg, Mette D., additional

Published
2014
Full Text
View/download PDF

26. Oral medicin.

Author

Rautava, Jaana, Herlofson, Bente Brokstad, Garming-Legert, Karin, Holmstrup, Palle, Richter, Svend, and Parikka, Mataleena

Published
2024

27. Thymic Function Predicts Response to Mesenchymal Stromal Cell Treatment in Chronic GvHD: A Phase II Clinical Study

Author

Boberg, Erik, Von Bahr, Lena, Heldring, Nina, Afram, Gabriel, Iacobaeus, Ellen, Lindström, Carina, Garming-Legert, Karin, Ljungman, Per, Sugars, Rachael, Davies, Lindsay, Kadri, Nadir, and Le Blanc, Katarina

Abstract

There is no established treatment for patients unresponsive to first line therapy for chronic graft versus host disease (cGVHD). Infusion of mesenchymal stromal cells (MSCs) is a promising alternative in this situation, but the treatment efficacy and mechanism of action have not yet been established. Furthermore, there is great need for biomarkers for selecting patients that are more likely to respond to MSC therapy.

Published
2017
Full Text
View/download PDF

28. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease.

Author

Marius Munneke, J., Björklund, Andreas T., Mjösberg, Jenny M., Garming-Legert, Karin, Bernink, Jochem H., Blom, Bianca, Huisman, Cynthia, van Oers, Marinus H. J., Spits, Hergen, Malmberg, Karl-Johan, and Hazenberg, Mette D.

Subjects
*LYMPHOID tissue, *STEM cell transplantation, *EPITHELIAL cells, *NEUTROPHILS, *MONOCYTES
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is widely used to treat hematopoietic cell disorders but is often complicated by graft-versus-host disease (GVHD), which causes severe epithelial damage. Here we have investigated longitudinally the effects of induction chemotherapy, conditioning radiochemotherapy, and allogeneic HSCT on composition, phenotype, and recovery of circulating innate lymphoid cells (ILCs) in 51 acute leukemia patients. We found that reconstitution of ILC1, ILC2, and NCR-ILC3 was slow compared with that of neutrophils and monocytes. NCR+ ILC3 cells, which are not present in the circulation of healthy persons, appeared both after induction chemotherapy and after allogeneic HSCT. Circulating patient ILCs before transplantation, as well as donor ILCs after transplantation, expressed activation (CD69), proliferation (Ki-67), and tissue homing markers for gut (α4β7, CCR6) and skin (CCR10 and CLA). The proportion of ILCs expressing these markers was associated with a decreased susceptibility to therapy-induced mucositis and acute GVHD. Taken together, these data suggest that ILC recovery and treatment-related tissue damage are interrelated and affect the development of GVHD. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results